Sam Brusco, Associate Editor05.24.22
Two diabetes technology leaders may soon be joining forces, potentially creating a giant in the diabetes management market.
According to a Bloomberg report, continuous glucose monitor (CGM) maker Dexcom is in talks to acquire tubeless insulin pump maker Insulet. The report states that anonymous sources “with knowledge of the matter” shared a deal could be reached in the coming weeks, and that discussions may still be delayed or fall through.
The two companies began a partnership in 2020 to combine Dexcom’s CGM with Insulet’s Omnipod wearable pump. The two have since worked together on further iterations—Insulet’s recently FDA approved Omnipod 5 integrates with the Dexcom G6 CGM.
Insulet has a market cap of $13.8 billion, and Dexcom has a market cap of $31.5 billion.
This report about a potential acquisition deal follows closely on the heels of Insulet CEO Shacey Petrovic stepping down due to personal family medical issues and circumstances. Beginning in June ResMed president of Sleep and Respiratory Care Jim Hollingshead will lead the company.
Combining the two companies would give Dexcom the means to make a closed-loop system for glucose monitoring and insulin delivery.
According to a Bloomberg report, continuous glucose monitor (CGM) maker Dexcom is in talks to acquire tubeless insulin pump maker Insulet. The report states that anonymous sources “with knowledge of the matter” shared a deal could be reached in the coming weeks, and that discussions may still be delayed or fall through.
The two companies began a partnership in 2020 to combine Dexcom’s CGM with Insulet’s Omnipod wearable pump. The two have since worked together on further iterations—Insulet’s recently FDA approved Omnipod 5 integrates with the Dexcom G6 CGM.
Insulet has a market cap of $13.8 billion, and Dexcom has a market cap of $31.5 billion.
This report about a potential acquisition deal follows closely on the heels of Insulet CEO Shacey Petrovic stepping down due to personal family medical issues and circumstances. Beginning in June ResMed president of Sleep and Respiratory Care Jim Hollingshead will lead the company.
Combining the two companies would give Dexcom the means to make a closed-loop system for glucose monitoring and insulin delivery.